Earlier this month at the 27th Annual Life Sciences of British Columbia Awards, PHC Ventures was named Strategic Partner of the Year, a recognition of their role in shaping the future… Read More
Exclusive commercial rights secured for the nanobody-based CD22 binder for next-generation CAR applications like in vivo CAR-T and CAR-M CD22 nanobody binder offers potential advantages compared to traditional antibody formats… Read More
First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line Independent Data Monitoring Committee (IDMC)… Read More
New partnership between GlycoNet and Alberta Innovates accelerates research commercialization in glycomics – the next frontier in biotechnology – to deliver transformative health solutions EDMONTON, AB – New funding investment… Read More
Sogroya® is the first-and-only once-weekly growth hormone treatment for both children and adults living with growth hormone deficiency (GHD)1 MISSISSAUGA, ON – Novo Nordisk has announced that Sogroya® (somapacitan injection)… Read More
